Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorRuijin Hospital
About this trial
To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).
Eligibility criteria
Qualifiers
Age ≥ 18 years, male or female.
Patients with a histopathologically confirmed diagnosis of peripheral T-cell lymphoma (PTCL) based on 2016 WHO classification
Previously treated with 3 or 6 cycles of a CHOP-like regimen as first-line therapy and considered primary refractory. Patients with anaplastic large cell lymphoma (ALCL) must have adequately received brentuximab vedotin (BV) as part of their first-line treatment.
Tumor tissue genotyping performed and results available prior to enrollment.
Disqualifiers
Has a prior malignancy other than the malignancies under study within 3 years without relieve
Primary CNS lymphoma
Known hypersensitivity to any study drug.
Pregnant or lactation
Trial design
Treatments tested in this trial
- Zeprumetostat+Azacitadine
- Zeprumetostat+Decitabine
- Zeprumetostat+Chidamide
- Zeprumetostat+Golidocitinib
Treatment groups
86 Participants
are divided into 4 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov